Ignite Creation Date:
2024-05-05 @ 9:10 PM
Last Modification Date:
2024-10-26 @ 10:00 AM
Study NCT ID:
NCT00833963
Status:
COMPLETED
Last Update Posted:
2019-05-16
First Post:
2009-01-30
Brief Title:
A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab Pertuzumab in Combination With Trastuzumab or Ado-Trastuzumab Emtansine
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin Perjeta in Combination With Herceptin or Kadcyla During Pregnancy or Within 7 Months Prior to Conception
Status:
COMPLETED
Status Verified Date:
2019-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MotHER
Brief Summary:
The MotHER Pregnancy Registry is a United States US-based prospective observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab herceptin-containing regimen with or without pertuzumab perjeta or ado-trastuzumab emtansine kadcyla during pregnancy or within 7 months prior to conception regardless of cancer stage at the time of trastuzumab pertuzumab or ado-trastuzumab emtansine exposure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None